Corcept Therapeutics presents data from MOMENTUM trial in hypercortisolism at American College of Cardiology Annual Scientific Session

Corcept Therapeutics  presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology Annual Scientific Session (ACC 2026).

MOMENTUM screened 1,086 patients with resistant hypertension (as defined by the American Heart Association’s criteria) and found that 27.3 percent, or 297 patients had hypercortisolism. This finding complements the results of Corcept’s CATALYST trial, which found hypercortisolism in 23.8 percent of the 1,057 patients screened with difficult-to-control type 2 diabetes. The prevalence of hypercortisolism in patients who had hemoglobin A1c (HbA1c) of 7.5 percent or higher and were taking 3 or more blood pressure medicines was 32.6 percent in MOMENTUM and 36.6 percent in CATALYST.

“Resistant hypertension increases the risk of cardiovascular events like heart attacks, strokes, and heart failure, as well as kidney damage,” said  Dr. Deepak L. Bhatt,  Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. “MOMENTUM shows that hypercortisolism contributes to resistant hypertension in over a quarter of patients and that screening for hypercortisolism in these challenging-to-treat patients may help physicians provide more personalized care.” Dr. Bhatt presented the data as Featured Clinical Research at ACC 2026, is a lead investigator and steering committee member for MOMENTUM, and a paid consultant to Corcept Therapeutics.

“It is now clear that hypercortisolism is more common than previously assumed in patients whose hypertension and diabetes don’t respond to standard-of-care treatments,” said Dr.  Bill Guyer, ,Corcept’s Chief Development Officer. “We are grateful to the investigators and patients who have participated in this research and hope that the findings will provide critical information to support increased screening for hypercortisolism, more accurate diagnoses and improved treatment options.”

MOMENTUM was the largest US-based trial ever conducted to assess the prevalence of hypercortisolism in patients with resistant hypertension. A total of 1,086 patients were screened at 50 sites across the United States. All patients had resistant hypertension as defined by the American Heart Association’s criteria (systolic blood pressure greater or equal to 130 mmHg despite taking 3 or more blood-pressure lowering medications, including a diuretic, or taking 4 or more blood-pressure lowering medications). Using a simple, standardized 1-mg dexamethasone suppression test (DST), 27 percent of these patients were found to have hypercortisolism.